Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by Sendero Wealth Management LLC

Sendero Wealth Management LLC increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,944 shares of the company’s stock after acquiring an additional 672 shares during the period. Sendero Wealth Management LLC’s holdings in Neurocrine Biosciences were worth $2,859,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Plato Investment Management Ltd raised its holdings in shares of Neurocrine Biosciences by 2,481.9% in the 3rd quarter. Plato Investment Management Ltd now owns 10,973 shares of the company’s stock worth $1,263,000 after purchasing an additional 10,548 shares during the period. Swiss National Bank boosted its holdings in Neurocrine Biosciences by 1.4% in the 3rd quarter. Swiss National Bank now owns 298,700 shares of the company’s stock worth $34,416,000 after acquiring an additional 4,100 shares during the period. Tri Ri Asset Management Corp acquired a new stake in Neurocrine Biosciences in the third quarter valued at approximately $3,236,000. KBC Group NV raised its stake in shares of Neurocrine Biosciences by 78.3% during the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after purchasing an additional 8,332 shares during the period. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Neurocrine Biosciences by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,421 shares of the company’s stock worth $2,238,000 after purchasing an additional 7,597 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Up 2.2 %

Shares of NBIX opened at $142.56 on Thursday. Neurocrine Biosciences, Inc. has a 1-year low of $110.95 and a 1-year high of $157.98. The stock has a market capitalization of $14.43 billion, a P/E ratio of 38.22 and a beta of 0.33. The business’s 50-day moving average price is $131.13 and its 200 day moving average price is $131.11.

Wall Street Analyst Weigh In

NBIX has been the subject of a number of analyst reports. UBS Group upped their price objective on shares of Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a report on Monday, December 16th. StockNews.com lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, BMO Capital Markets lowered their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $164.81.

Insider Transactions at Neurocrine Biosciences

In other news, insider Ingrid Delaet sold 272 shares of the firm’s stock in a transaction on Tuesday, December 31st. The stock was sold at an average price of $138.10, for a total value of $37,563.20. Following the completion of the sale, the insider now owns 2,507 shares of the company’s stock, valued at $346,216.70. This trade represents a 9.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,694 shares of company stock valued at $479,230 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.